The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2015 Jul 2

PMID 26132566

Citations 2

Authors

Zbigniew Adamczewski

Mariusz Stasiolek

Boleslaw Karwowski

Marek Dedecjus

Daria Orszulak-Michalak

Anna Merecz

Przemyslaw W Sliwka

Bartosz Pula

Andrzej Lewinski

Affiliations

Soon will be listed here.

Abstract

Background: Administration of diagnostic activities of 131I, performed in order to detect thyroid remnants after surgery and/or thyroid cancer recurrence/metastases, may lead to reduction of iodine uptake. This phenomenon is called "thyroid stunning". We estimated radiation absorbed dose-dependent changes in genetic material, in particular in sodium iodide symporter (NIS) gene promoter, and NIS protein level in human thyrocytes (HT).

Materials And Methods: We used unmodified HT isolated from patients subjected to thyroidectomy exposed to 131I in culture. The different 131I activities applied were calculated to result in absorbed doses of 5, 10, and 20 Gy.

Results: According to flow cytometry analysis and comet assay, 131I did not influence the HT viability in culture. Temporary increase of 8-oxo-dG concentration in HT directly after 24 h (p < 0.05) and increase in the number of AP-sites 72 h after termination of exposition to 20 Gy dose (p < 0.0001) were observed. The signs of dose-dependent DNA damage were not associated with essential changes in the NIS expression on mRNA and protein levels.

Conclusions: Our observation constitutes a first attempt to evaluate the effect of the absorbed dose of 131I on HT. The results have not confirmed the theory that the "thyroid stunning" reduces the NIS protein synthesis.

Citing Articles

How Clustered DNA Damage Can Change the Electronic Properties of ds-DNA-Differences between GAG, GAG, and GAG.

Karwowski B Biomolecules. 2023; 13(3).

PMID: 36979452 PMC: 10046028. DOI: 10.3390/biom13030517.

The Molecular Effect of Diagnostic Absorbed Doses from I on Papillary Thyroid Cancer Cells In Vitro.

Stasiolek M, Adamczewski Z, Sliwka P, Pula B, Karwowski B, Merecz-Sadowska A Molecules. 2017; 22(6).

PMID: 28617334 PMC: 6152650. DOI: 10.3390/molecules22060993.

References

Cadet J, Loft S, Olinski R, Evans M, Bialkowski K, Wagner J . Biologically relevant oxidants and terminology, classification and nomenclature of oxidatively generated damage to nucleobases and 2-deoxyribose in nucleic acids. Free Radic Res. 2012; 46(4):367-81. PMC: 3864884. DOI: 10.3109/10715762.2012.659248. View

Medvedec M . Thyroid stunning in vivo and in vitro. Nucl Med Commun. 2005; 26(8):731-5. DOI: 10.1097/01.mnm.0000169380.92270.73. View

Kogai T, Brent G . The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012; 135(3):355-70. PMC: 3408573. DOI: 10.1016/j.pharmthera.2012.06.007. View

Silberstein E . Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007; 48(7):1043-6. DOI: 10.2967/jnumed.107.040311. View

Lundh C, Norden M, Nilsson M, Forssell-Aronsson E . Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med. 2007; 48(3):481-6. View

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View

McDougall I . 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun. 1997; 18(6):505-12. DOI: 10.1097/00006231-199706000-00002. View

Arad E, Flannery K, Wilson G, OMara R . Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nucl Med. 1990; 15(10):676-7. View

Karam M, Gianoukakis A, Feustel P, Cheema A, Postal E, Cooper J . Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun. 2003; 24(5):489-95. DOI: 10.1097/00006231-200305000-00002. View

10.

Wu H, Hseu H, Lin W, Wang S, Liu Y . Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imaging. 2004; 32(2):167-73. DOI: 10.1007/s00259-004-1655-1. View

11.

Cholewinski S, Yoo K, Klieger P, OMara R . Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med. 2000; 41(7):1198-202. View

12.

Maynard S, Schurman S, Harboe C, de Souza-Pinto N, Bohr V . Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis. 2008; 30(1):2-10. PMC: 2639036. DOI: 10.1093/carcin/bgn250. View

13.

Muratet J, Daver A, Minier J, Larra F . Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998; 39(9):1546-50. View

14.

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W . European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154(6):787-803. DOI: 10.1530/eje.1.02158. View

15.

Singh N, McCoy M, Tice R, Schneider E . A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988; 175(1):184-91. DOI: 10.1016/0014-4827(88)90265-0. View

16.

Huic D, Medvedec M, Dodig D, Popovic S, IVANCEVIC D, Pavlinovic Z . Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I. Nucl Med Commun. 1996; 17(10):839-42. View

17.

Leger F, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A . Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998; 25(3):242-6. DOI: 10.1007/s002590050223. View

18.

Park H, Perkins O, Edmondson J, SCHNUTE R, Manatunga A . Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994; 4(1):49-54. DOI: 10.1089/thy.1994.4.49. View

19.

Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G . Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med. 2002; 43(6):828-34. View

20.

Park H, Park Y, Zhou X . Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid. 1997; 7(2):277-80. DOI: 10.1089/thy.1997.7.277. View